Imran Plumb, MD
Internal Medicine · Durant, OKNPI 1275827305
Payments from drug & device makers
Across 287 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$568
- Novo Nordisk$491
- Gilead$437
- Johnson & Johnson$410
- Mylan Specialty L.p.$333
- GSK$280
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,79898%
- Education$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $568 |
| Novo Nordisk | 28 | $491 |
| Gilead | 30 | $437 |
| Johnson & Johnson | 13 | $410 |
| Mylan Specialty L.p. | 20 | $333 |
| GSK | 15 | $280 |
| Amgen | 17 | $271 |
| Lilly USA, LLC | 18 | $252 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $203 |
| AstraZeneca | 12 | $193 |
| Sunovion Pharmaceuticals Inc. | 11 | $180 |
| Medtronic | 10 | $147 |
| Astellas Pharma US Inc | 2 | $119 |
| Pfizer | 6 | $97 |
| Abbott | 4 | $85 |
| Sanofi-aventis U.S. LLC | 6 | $84 |
| Novartis | 4 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $60 |
| Exact Sciences | 4 | $58 |
| Alkermes, Inc. | 3 | $52 |
| Biohaven Pharmaceuticals, Inc. | 2 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Dexcom, Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Merck | 2 | $32 |
| Indivior Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Vertex | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| GRT US Holding, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Medicomp Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$147
- LONHALA MAGNAIR$103
How this compares
$4,889 in reported general payments places this provider in the 85th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 187 | $162,577 |
| OzempicSemaglutide | 121 | $151,391 |
| EliquisApixaban | 221 | $143,298 |
| MounjaroTirzepatide | 80 | $96,706 |
| JardianceEmpagliflozin | 88 | $90,575 |
| LinzessLinaclotide | 74 | $70,664 |
| TrulicityDulaglutide | 59 | $61,107 |
| FarxigaDapagliflozin Propanediol | 55 | $54,238 |
| JanuviaSitagliptin Phosphate | 41 | $48,706 |
| XifaxanRifaximin | 16 | $48,564 |
| Invega SustennaPaliperidone Palmitate | 12 | $43,072 |
| VraylarCariprazine Hcl | 22 | $34,953 |
| XareltoRivaroxaban | 51 | $32,417 |
| MovantikNaloxegol Oxalate | 79 | $31,660 |
| MyrbetriqMirabegron | 52 | $29,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Breo Ellipta | $280 | $203,435254 claims |
| Lilly USA, LLCMounjaro, Trulicity | $252 | $157,813139 claims |
| Novo NordiskOzempic | $491 | $151,391121 claims |
| PfizerEliquis | $97 | $143,298221 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $35 | $128,955134 claims |
| AbbVieLinzess, Vraylar | $568 | $105,61796 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto, Invokana | $410 | $81,37574 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $193 | $79,61994 claims |
| MerckJanuvia | $32 | $48,70641 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $203 | $48,56416 claims |
| Astellas Pharma US IncMyrbetriq | $119 | $29,11752 claims |
| NovartisEntresto | $62 | $20,40126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Durant
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
- Elise WiesnerNorman$584K
- Steve EgwuonwuLawton$464K
- Mousumi SomTulsa$391K
- Jesse RichardsTulsa$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.